Adlai Nortye Secures Cetuximab for AN4035 Phase I Trial

Adlai Nortye entered clinical trial collaboration and supply agreements with Lilly and Merck KGaA to provide cetuximab for its Phase I AN4035 trial, including monotherapy and combination arms in CEACAM5-enriched, RAS-addicted solid tumors.